Advertisement

GLP-1s

CVS Health CEO David Joyner is skeptical as to whether the evidence backs GLP-1 investment right now. “Everybody intuitively believes these medications create long-term health benefits, but the evidence hasn’t yet demonstrated that paying today’s prices generates enough downstream savings,”…

Novo Nordisk has agreed to evaluate a GLP-1 implant developed by biopharmaceutical company Vivani Medical. The implant, called NPM-139, delivers semaglutide through a titanium reservoir fitted with a membrane containing microscopic channels designed to release the drug at a steady…

A wave of new research and policy developments is reshaping how health system leaders think about GLP-1 medications — from telehealth prescribing gaps to Medicare’s new coverage bridge. Here are six recent findings: 1. The share of employers covering GLP-1s…

Joe Northup, MD, associate professor of surgery at Vanderbilt University School of Medicine and director of metabolic and bariatric surgery at Vanderbilt University Medical Center in Nashville, Tenn., was elected the 40th president of the American Society for Metabolic and…

The federal government has not broadly promoted Medicare’s recent $50-a-month obesity-drug benefit, so two GLP-1 manufacturers, Eli Lilly and Novo Nordisk, are touting it themselves, according to Cost Curve.  The Medicare GLP-1 Bridge, which launched July 1, allows eligible Part…

Advertisement

Peptides have become one of the most closely watched regulatory questions in healthcare this summer, with a federal advisory committee vote set for July 23-24 that could reshape what’s legally available to prescribers, wellness clinics and patients nationwide. What are…

Many telehealth platforms selling GLP-1s online prescribe the drugs without requiring a clinician to interact with the patient in real time, according to a secret shopper study conducted by researchers at Yale University School of Medicine and published July 6…

A cryptocurrency-fueled gray-market peptide market has surpassed a $100 million annual run rate as demand for lower-cost weight loss drugs continues to grow, according to a June 4 Chainalysis report. The report found that some Chinese chemical manufacturers that once…

Advertisement